ClinVar Miner

Submissions for variant NM_000124.4(ERCC6):c.2167C>T (p.Gln723Ter) (rs151242354)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 5
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Baylor Miraca Genetics Laboratories, RCV000170378 SCV000807646 pathogenic Cockayne syndrome B 2017-09-01 criteria provided, single submitter clinical testing This mutation has been previously reported as disease-causing and was found twice in our laboratory in trans with another pathogenic mutation in patients, including one with suspected diagnosis of Cockayne syndrome. Heterozygotes are expected to be asymptomatic carriers.
Claritas Genomics RCV000170378 SCV000222793 pathogenic Cockayne syndrome B 2013-01-07 criteria provided, single submitter clinical testing
Counsyl RCV000667973 SCV000792505 likely pathogenic DE SANCTIS-CACCHIONE SYNDROME; Cerebro-oculo-facio-skeletal syndrome; Cockayne syndrome B 2017-06-26 criteria provided, single submitter clinical testing
GeneDx RCV000256036 SCV000321604 pathogenic not provided 2017-05-23 criteria provided, single submitter clinical testing The Q723X variant in the ERCC6 gene has been reported previously in congenital Cockayne syndrome, in an affected individual who was compound heterozygous for the Q723X variant and another ERCC6 mutation (Laugel et al., 2010). This variant is predicted to cause loss of normal protein function either through protein truncation or nonsense-mediated mRNA decay. The Q723X variant was not observed in the homozgyous state or at any significant frequency in approximately 6500 individuals of European and African American ancestry by the NHLBI Exome Sequencing Project. We interpret Q723X as a pathogenic variant.
Illumina Clinical Services Laboratory,Illumina RCV000778283 SCV000914459 pathogenic ERCC6-Related Disorders 2018-12-10 criteria provided, single submitter clinical testing The ERCC6 c.2167C>T (p.Gln723Ter) variant is a stop-gained in the splice region variant that is predicted to result in premature truncation of the protein. The p.Gln723Ter variant has been reported in two studies in which it is found in a total of 12 individuals affected with Cockayne syndrome-B, including in two in a homozygous state and in ten in a compound heterozygous state with a unique null variant (Laugel et al. 2010; Calmels et al. 2018). Control data are unavailable for this variant, which is reported at a frequency of 0.00047 in the European American population of the Exome Sequencing Project. The p.Gln723Ter variant has not been reported in the literature in association with macular degeneration or cerebrooculofacioskeletal syndrome. Based on the collective evidence and the potential impact of stop-gained variants, the p.Gln723Ter variant is classified as pathogenic for ERCC6-related disorders. This variant was observed by ICSL as part of a predisposition screen in an ostensibly healthy population.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.